LG Life Sciences’ Novel HBV Treatment Proven for Its Efficacy and Safety

Published: 2004-12-16 07:00:00

Updated: 2004-12-16 07:00:00

LG Life Sciences, Ltd (LGLS) reported the interim results from the current Phase 2 clinical trial of LB80380, regarded as the next generation treatment for hepatitis B virus (HBV) infection. The results were presented at the Asia Pacific Association for the Study of the Liver (APASL) conference held in New Delhi, India.

While most of currently approved HBV treatments exhibit shorcomings suc...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.